SKYRIZI 360 mg, solution for injection in a cartridge cartridge, 2.4 ml
Active ingredients: Risankizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectioncartridge, 2.4 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SKYRIZI 360 mg, solution injectable en cartouche
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 cartouche(s) copolymère de cyclooléfines (COC) de 2,4 mL avec dispositif(s) d'administration
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61512595CIP73026258CIP133400930262580Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RISANKIZUMABsolution | 360 mg · une cartouche de 2,4 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.